Throughout the article, the names of the COVID-19 vaccinations should be identified by their scientific labels, not the manufacturers’ names. “AstraZeneca” should be “ChAdOx1 nCoV-19” and “Johnson & Johnson/Janssen” should be “Ad26.COV2.S.”
In the third paragraph on page 246, the sentence that reads “All 3 patients with VITT were positive for antibodies against PF4-polyanion complexes enzyme-linked immunosorbent assay (ELISA) optical density at 405 nm was 2.41 for patient 1, 1.21 for patient 2, and 2.75 for patient 3)” should read “All 3 patients with VITT were positive for antibodies against PF4-polyanion complexes where the enzyme-linked immunosorbent assay (ELISA) optical density at 405 nm was 2.41 for patient 1, 1.21 for patient 2, and 2.75 for patient 3.”
In the paragraph on page 247 that begins “The binding response and dissociation rates,” the sentence that begins “The binding response was measured” should start with “For all 3 VITT patients, the binding response was measured.” In the next paragraph, the reduction in binding for the additional 3 surface amino acids on PF4 that were distinct from the heparin-binding region should be ">50%," not "<50%."
In Table 1 on page 247, in the eighth row of the first column, “PF4 SRA or PEA (14C-serotonin ≥20%)” should read “PF4 SRA (14C-serotonin ≥20%) or PEA.”
In the Acknowledgments section on page 249, a grant from the Public Health Agency of Canada to author Donald M. Arnold should have been mentioned.
